ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be safe for human beings and efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future.
Exlgasse 20a
6020 Innsbruck
Tyrol
Contact: Heinz Schwer (CEO)
Telephone: +43 (512) 272061
Email: office@viratherapeutics.com
Website